Cargando…

Targeting the Choroid Plexuses for Protein Drug Delivery

Delivery of therapeutic agents to the central nervous system is challenged by the barriers in place to regulate brain homeostasis. This is especially true for protein therapeutics. Targeting the barrier formed by the choroid plexuses at the interfaces of the systemic circulation and ventricular syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Bryniarski, Mark A., Ren, Tianjing, Rizvi, Abbas R., Snyder, Anthony M., Morris, Marilyn E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602164/
https://www.ncbi.nlm.nih.gov/pubmed/33066423
http://dx.doi.org/10.3390/pharmaceutics12100963
_version_ 1783603613767041024
author Bryniarski, Mark A.
Ren, Tianjing
Rizvi, Abbas R.
Snyder, Anthony M.
Morris, Marilyn E.
author_facet Bryniarski, Mark A.
Ren, Tianjing
Rizvi, Abbas R.
Snyder, Anthony M.
Morris, Marilyn E.
author_sort Bryniarski, Mark A.
collection PubMed
description Delivery of therapeutic agents to the central nervous system is challenged by the barriers in place to regulate brain homeostasis. This is especially true for protein therapeutics. Targeting the barrier formed by the choroid plexuses at the interfaces of the systemic circulation and ventricular system may be a surrogate brain delivery strategy to circumvent the blood-brain barrier. Heterogenous cell populations located at the choroid plexuses provide diverse functions in regulating the exchange of material within the ventricular space. Receptor-mediated transcytosis may be a promising mechanism to deliver protein therapeutics across the tight junctions formed by choroid plexus epithelial cells. However, cerebrospinal fluid flow and other barriers formed by ependymal cells and perivascular spaces should also be considered for evaluation of protein therapeutic disposition. Various preclinical methods have been applied to delineate protein transport across the choroid plexuses, including imaging strategies, ventriculocisternal perfusions, and primary choroid plexus epithelial cell models. When used in combination with simultaneous measures of cerebrospinal fluid dynamics, they can yield important insight into pharmacokinetic properties within the brain. This review aims to provide an overview of the choroid plexuses and ventricular system to address their function as a barrier to pharmaceutical interventions and relevance for central nervous system drug delivery of protein therapeutics. Protein therapeutics targeting the ventricular system may provide new approaches in treating central nervous system diseases.
format Online
Article
Text
id pubmed-7602164
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76021642020-11-01 Targeting the Choroid Plexuses for Protein Drug Delivery Bryniarski, Mark A. Ren, Tianjing Rizvi, Abbas R. Snyder, Anthony M. Morris, Marilyn E. Pharmaceutics Review Delivery of therapeutic agents to the central nervous system is challenged by the barriers in place to regulate brain homeostasis. This is especially true for protein therapeutics. Targeting the barrier formed by the choroid plexuses at the interfaces of the systemic circulation and ventricular system may be a surrogate brain delivery strategy to circumvent the blood-brain barrier. Heterogenous cell populations located at the choroid plexuses provide diverse functions in regulating the exchange of material within the ventricular space. Receptor-mediated transcytosis may be a promising mechanism to deliver protein therapeutics across the tight junctions formed by choroid plexus epithelial cells. However, cerebrospinal fluid flow and other barriers formed by ependymal cells and perivascular spaces should also be considered for evaluation of protein therapeutic disposition. Various preclinical methods have been applied to delineate protein transport across the choroid plexuses, including imaging strategies, ventriculocisternal perfusions, and primary choroid plexus epithelial cell models. When used in combination with simultaneous measures of cerebrospinal fluid dynamics, they can yield important insight into pharmacokinetic properties within the brain. This review aims to provide an overview of the choroid plexuses and ventricular system to address their function as a barrier to pharmaceutical interventions and relevance for central nervous system drug delivery of protein therapeutics. Protein therapeutics targeting the ventricular system may provide new approaches in treating central nervous system diseases. MDPI 2020-10-14 /pmc/articles/PMC7602164/ /pubmed/33066423 http://dx.doi.org/10.3390/pharmaceutics12100963 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bryniarski, Mark A.
Ren, Tianjing
Rizvi, Abbas R.
Snyder, Anthony M.
Morris, Marilyn E.
Targeting the Choroid Plexuses for Protein Drug Delivery
title Targeting the Choroid Plexuses for Protein Drug Delivery
title_full Targeting the Choroid Plexuses for Protein Drug Delivery
title_fullStr Targeting the Choroid Plexuses for Protein Drug Delivery
title_full_unstemmed Targeting the Choroid Plexuses for Protein Drug Delivery
title_short Targeting the Choroid Plexuses for Protein Drug Delivery
title_sort targeting the choroid plexuses for protein drug delivery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602164/
https://www.ncbi.nlm.nih.gov/pubmed/33066423
http://dx.doi.org/10.3390/pharmaceutics12100963
work_keys_str_mv AT bryniarskimarka targetingthechoroidplexusesforproteindrugdelivery
AT rentianjing targetingthechoroidplexusesforproteindrugdelivery
AT rizviabbasr targetingthechoroidplexusesforproteindrugdelivery
AT snyderanthonym targetingthechoroidplexusesforproteindrugdelivery
AT morrismarilyne targetingthechoroidplexusesforproteindrugdelivery